Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Capstone Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,763,438

148 payments

Through program year 2022, Capstone Clinical Research Inc is reported as receiving $1,763,438 in research payments, across 148 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $37,748 3
2021 Research $257,174 26
2020 Research $720,129 40
2019 Research $748,388 79

Breakdown

Who paid Research payments · program years 2019–2022
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $796,902 7 payments
  2. Allergan Inc. $599,093 73 payments
  3. Sunovion Pharmaceuticals Inc. $118,032 22 payments
  4. F. Hoffmann-La Roche AG $81,489 17 payments
  5. Supernus Pharmaceuticals, Inc. $52,183 17 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $47,139 1 payment
  7. AbbVie, Inc. $37,748 3 payments
  8. ACADIA Pharmaceuticals Inc $14,227 4 payments
  9. Biohaven Pharmaceuticals, Inc. $11,750 3 payments
  10. Genentech, Inc. $4,875 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder $201,491 2 payments
  2. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00013) $185,922 1 payment
  3. Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD $141,047 1 payment
  4. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00013 $140,547 1 payment
  5. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder $125,265 12 payments
  6. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $118,512 13 payments
  7. Dasotraline Binge Eating Disorder Extension Study $118,032 22 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $104,047 1 payment
  9. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $98,009 1 payment
  10. V1a 2 in Pediatric Autism $81,489 17 payments
What the money was spent on Research payments · program years 2019–2022
  1. Other $47,139 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record